Literature DB >> 15476589

Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells.

Julie M Radeff1, Zsolt Nagy, Paula H Stern.   

Abstract

UNLABELLED: The role of small G-proteins in PTH-stimulated PKC translocation and IL-6 promoter expression in UMR-106 cells was determined. The effects of PTH(1-34) and PTH(3-34) in stimulating PKCalpha translocation and IL-6 were inhibited by agents that interfere with the activity of small G-proteins of the Rho family and with the downstream kinase Rho kinase.
INTRODUCTION: Activation of protein kinase C (PKC) is a signaling mechanism by which parathyroid hormone (PTH) modulates interleukin-6 (IL-6) in osteoblasts, leading to osteoclastogenesis and bone resorption. PKCalpha and PKCbetaI are translocated after treatment with PTH in UMR-106 osteoblastic cells; however, the pathway leading to PKC isozyme translocation is not established. Diacylglycerol (DAG) generation from phospholipase D (PLD) is one pathway of PKC activation, and PTH-mediated PLD activity is dependent on small G-proteins of the Rho family. This study investigated whether Rho proteins modulate the PKCalpha translocation and IL-6 promoter activity stimulated by PTH in UMR-106 cells.
MATERIALS AND METHODS: UMR-106 cells were treated with PTH(1-34) or PTH(3-34). PKC translocation was determined by immunofluorescence, Rho A activation by Rhotekin assay and by translocation assessed by Western blotting in membrane and cytosol fractions, and IL-6 promoter expression by luciferase assay. RESULTS AND
CONCLUSIONS: Inhibition of Rho proteins with Clostridium difficile toxin B or inhibition of Rho prenylation with GGTI attenuated PTH(1-34)- and PTH(3-34)-stimulated translocation of endogenous PKCalpha and IL-6 promoter activity. Expression of a constitutively active RhoA (RhoA63L) mimicked the effect of PTH(1-34) or PTH(3-34) to promote membrane localization of PKCalpha, whereas cells expressing a dominant negative RhoA (RhoA19N) did not respond to PTH(1-34) or PTH(3-34). The Rho kinase inhibitor Y27632 attenuated PTH(1-34)- and PTH(3-34)-stimulated PKCalpha translocation and IL-6 promoter activation. Rho seemed to be acting at a step before production of diacylglycerol (DAG), because the stimulation of PKCalpha translocation by the DAG mimetic phorbol 12,13 dibutyrate (PDBu) was unaffected by C. difficile toxin B or Y27632. These results indicate that Rho proteins are an important component of PTH signaling in osteoblastic cells and provide further demonstration of convergence between PKC and small G-protein signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476589     DOI: 10.1359/JBMR.040806

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

1.  Osteoclastogenic activity and RANKL expression are inhibited in osteoblastic cells expressing constitutively active Gα(12) or constitutively active RhoA.

Authors:  Jun Wang; Paula H Stern
Journal:  J Cell Biochem       Date:  2010-12-15       Impact factor: 4.429

2.  Parathyroid hormone regulation of hypoxia-inducible factor signaling in osteoblastic cells.

Authors:  Alice Wong; Gabriela G Loots; Clare E Yellowley; Andréa C Dosé; Damian C Genetos
Journal:  Bone       Date:  2015-07-04       Impact factor: 4.398

3.  Parathyroid hormone regulates osteoblast differentiation in a Wnt/β-catenin-dependent manner.

Authors:  Ye Tian; Ying Xu; Qin Fu; Ming He
Journal:  Mol Cell Biochem       Date:  2011-05-01       Impact factor: 3.396

Review 4.  Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

Authors:  Ming Dong; Bryan P Yan; James K Liao; Yat-Yin Lam; Gabriel W K Yip; Cheuk-Man Yu
Journal:  Drug Discov Today       Date:  2010-06-25       Impact factor: 7.851

5.  Antagonist minigenes identify genes regulated by parathyroid hormone through G protein-selective and G protein co-regulated mechanisms in osteoblastic cells.

Authors:  J Wang; A Gilchrist; P H Stern
Journal:  Cell Signal       Date:  2010-10-19       Impact factor: 4.315

6.  Regulation of interleukin-6 expression in osteoblasts by oxidized phospholipids.

Authors:  Wendy Tseng; Jinxiu Lu; Gail A Bishop; Andrew D Watson; Andrew P Sage; Linda Demer; Yin Tintut
Journal:  J Lipid Res       Date:  2009-11-11       Impact factor: 5.922

7.  The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival.

Authors:  Tomohiko Yoshida; Mary F Clark; Paula H Stern
Journal:  J Cell Biochem       Date:  2009-04-01       Impact factor: 4.429

8.  Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease.

Authors:  Ming Dong; Xin Jiang; James K Liao; Bryan P Yan
Journal:  Clin Cardiol       Date:  2013-03-28       Impact factor: 2.882

9.  Rho GTPase signaling and PTH 3-34, but not PTH 1-34, maintain the actin cytoskeleton and antagonize bisphosphonate effects in mouse osteoblastic MC3T3-E1 cells.

Authors:  Nikolas H Kazmers; Sophia A Ma; Tomohiko Yoshida; Paula H Stern
Journal:  Bone       Date:  2009-04-08       Impact factor: 4.398

10.  Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women.

Authors:  Alison Gartland; Kristen K Skarratt; Lynne J Hocking; Claire Parsons; Leanne Stokes; Niklas Rye Jørgensen; William D Fraser; David M Reid; James A Gallagher; James S Wiley
Journal:  Eur J Hum Genet       Date:  2012-01-11       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.